Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) EBIT: 2013-2025

Historic EBIT for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to -$44.3 million.

  • Coherus Oncology's EBIT rose 5.38% to -$44.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$92.7 million, marking a year-over-year increase of 58.48%. This contributed to the annual value of -$111.7 million for FY2024, which is 45.05% up from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's EBIT is -$44.3 million, which was up 2.53% from -$45.5 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's EBIT peaked at $42.6 million during Q4 2024, and registered a low of -$167.4 million during Q1 2021.
  • Moreover, its 3-year median value for EBIT was -$45.4 million (2025), whereas its average is -$40.9 million.
  • Per our database at Business Quant, Coherus Oncology's EBIT tumbled by 509.51% in 2021 and then skyrocketed by 161.83% in 2024.
  • Over the past 5 years, Coherus Oncology's EBIT (Quarterly) stood at -$39.5 million in 2021, then tumbled by 30.21% to -$51.5 million in 2022, then plummeted by 33.81% to -$68.9 million in 2023, then skyrocketed by 161.83% to $42.6 million in 2024, then grew by 5.38% to -$44.3 million in 2025.
  • Its EBIT stands at -$44.3 million for Q3 2025, versus -$45.5 million for Q2 2025 and -$45.4 million for Q1 2025.